Profile data is unavailable for this security.
About the company
IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
- Revenue in SGD (TTM)5.96m
- Net income in SGD-10.79m
- Incorporated2004
- Employees56.00
- LocationIX Biopharma Ltd1 Kim Seng Promenade#14-01 Great World City 237994SingaporeSGP
- Phone+65 62352270
- Fax+65 62352170
- Websitehttps://www.ixbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLIS Technologies Ltd | 9.08m | 508.70k | 19.14m | 10.00 | 32.20 | 2.12 | 20.70 | 2.11 | 0.0006 | 0.0006 | 0.0091 | 0.009 | 0.8955 | -- | 8.41 | -- | 5.02 | -2.45 | 5.64 | -2.90 | -- | -- | 5.60 | -2.40 | 8.30 | 23.45 | 0.0328 | -- | 12.61 | 6.52 | 147.85 | 11.14 | 34.35 | -- |
| Can Fite Biopharma Ltd | 897.05k | -9.91m | 19.83m | 5.00 | -- | 4.87 | -- | 22.11 | -0.0176 | -0.0176 | 0.0017 | 0.0055 | 0.0787 | -- | -- | 498,409.10 | -86.95 | -102.29 | -115.77 | -131.07 | -- | -- | -1,105.10 | -1,105.36 | -- | -- | 0.00 | -- | -8.27 | -27.92 | 24.96 | -- | -42.92 | -- |
| Nyrada Inc | 2.96m | -1.21m | 20.03m | -- | -- | 3.97 | -- | 6.78 | -0.0081 | -0.0081 | 0.0209 | 0.0277 | 0.6147 | -- | -- | -- | -25.13 | -53.28 | -29.75 | -62.52 | -- | -- | -40.89 | -236.15 | -- | -- | 0.00 | -- | 115.55 | 46.42 | 82.12 | -- | -- | -- |
| SMAIO SA | 6.96m | -2.54m | 20.09m | 43.00 | -- | 1.76 | -- | 2.88 | -0.3383 | -0.3383 | 0.929 | 1.54 | 0.3738 | 0.3816 | 9.41 | 132,756.80 | -13.65 | -7.87 | -15.68 | -18.43 | 88.45 | 96.04 | -36.52 | -22.48 | 4.25 | -- | 0.236 | -- | 212.18 | 114.99 | -62.80 | -- | -- | -- |
| Extrawell Pharmaceutical Holdings Ltd | 10.22m | -28.19m | 20.26m | 159.00 | -- | 0.1052 | -- | 1.98 | -0.0682 | -0.0682 | 0.0247 | 0.4657 | 0.0433 | 5.90 | 11.81 | 371,685.50 | -11.83 | 1.01 | -12.32 | 1.06 | 48.70 | 50.54 | -273.51 | 18.00 | 3.31 | -0.0753 | 0.0977 | 0.00 | -18.57 | -7.91 | -226.06 | -- | -3.20 | -- |
| IX Biopharma Ltd | 5.96m | -10.79m | 20.32m | 56.00 | -- | 4.07 | -- | 3.41 | -0.014 | -0.014 | 0.0078 | 0.0057 | 0.3013 | 4.20 | 1.99 | -- | -54.58 | -39.79 | -86.37 | -52.71 | 17.59 | 50.67 | -181.14 | -150.87 | 0.7053 | -2.42 | 0.5451 | -- | 0.778 | 54.77 | -12.26 | -- | -29.94 | -- |
| Lasa Supergenerics Ltd | 16.67m | -3.11m | 20.56m | 77.00 | -- | -- | -- | 1.23 | -3.92 | -3.92 | 20.94 | -- | -- | -- | -- | 13,586,300.00 | -- | -3.86 | -- | -5.34 | 26.41 | 32.53 | -18.65 | -5.30 | -- | -4.49 | -- | -- | -19.47 | -9.26 | 43.73 | -- | -- | -- |
| Gelteq Ltd | 0.00 | -2.05m | 20.58m | -- | -- | 1.09 | -- | -- | -0.1597 | -0.1597 | 0.00 | 1.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38 | -32.41 | 0.0605 | -- | -- | -- | -72.77 | -- | -- | -- |
| Bright Green Corp | 0.00 | -13.35m | 20.63m | 5.00 | -- | 1.54 | -- | -- | -0.0538 | -0.0538 | 0.00 | 0.0519 | 0.00 | -- | -- | 0.00 | -47.48 | -- | -72.55 | -- | -- | -- | -- | -- | -- | -- | 0.0494 | -- | -- | -- | 52.54 | -- | -- | -- |
| Phapros Tbk PT | 68.47m | -3.96m | 20.83m | 1.38k | -- | 0.3573 | 259.50 | 0.3042 | -55.54 | -55.54 | 960.00 | 817.32 | 0.4587 | 1.44 | 1.51 | 547,082,300.00 | -2.69 | 2.07 | -4.42 | 4.04 | 48.90 | 51.79 | -5.86 | 3.68 | 1.10 | 0.0247 | 0.5173 | -- | -13.21 | -0.1734 | -78.77 | -46.21 | -24.81 | -- |
| BIOGENED SA | 34.68m | 1.76m | 20.94m | 204.00 | 11.92 | 1.63 | 6.91 | 0.6038 | 2.18 | 2.18 | 43.06 | 15.96 | 1.26 | 1.90 | 3.84 | 506,045.20 | 6.37 | 3.15 | 9.59 | 4.46 | 68.91 | 68.04 | 5.07 | 3.58 | 1.06 | 4.18 | 0.3519 | -- | 20.02 | 18.88 | 50.74 | 34.99 | 9.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Pheim Asset Management Sdn. Bhd.as of 30 Jun 2024 | 2.40m | 0.27% |
| Pheim Asset Management (Asia) Pte Ltd.as of 30 Dec 2021 | 0.00 | 0.00% |
